Altered neuronal markers following treatment with mood stabilizer and antipsychotic drugs indicate an increased likelihood of neurotransmitter release

Clinical Psychopharmacology and Neuroscience

Volumn 10, Issue 1, 2012, Pages 25-33

  Scarr, Elizabeth ^a   Dean, Brian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antipsychotic agents; Lithium; Nerve tissue proteins; Neural cell adhesion molecules; SNARE proteins

Indexed keywords

ALCOHOL; ALPHA SYNUCLEIN; HALOPERIDOL; LITHIUM; NERVE CELL ADHESION MOLECULE; OLANZAPINE; SYNAPTOBREVIN; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; MALE; MENTAL DISEASE; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

EID: 84861403030     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2012.10.1.25     Document Type: Article

References (56)

1. Pompili M, Rihmer Z, Innamorati M, Lester D, Girardi P, Tatarelli R. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother 2009;9:109-136.
2. Montross LP, Kasckow J, Golshan S, Solorzano E, Lehman D, Zisook S. Suicidal ideation and suicide attempts among middle-aged and older patients with schizophrenia spectrum disorders and concurrent subsyndromal depression. J Nerv Ment Dis 2008;196:884-890.
3. Newberg AR, Catapano LA, Zarate CA, Manji HK. Neuro-biology of bipolar disorder. Expert Rev Neurother 2008;8: 93-110.
4. Dean B. Changes in the molecular structure of the brain in bipolar disorder: findings using human postmortem brain tissue. World J Biol Psychiatry 2002;3:125-132.
5. Scarr E, Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother 2009;9:73-86.
6. Lewis DA, González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008;33:141-165. (Pubitemid 350191315)
7. Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008;29:445-453.
8. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi- Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 2005;27(Suppl A):S16-S24. (Pubitemid 41356605)
9. Honer WG, Falkai P, Young C, Wang T, Xie J, Bonner J, et al. Cingulate cortex synaptic terminal proteins and neural cell adhesion molecule in schizophrenia. Neuroscience 1997;78:99-110. (Pubitemid 27132588)
10. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P, et al. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry 1997;54:559-566. (Pubitemid 27258554)
11. Thompson PM, Sower AC, Perrone-Bizzozero NI. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol Psychiatry 1998;43:239-243. (Pubitemid 28085669)
12. Fatemi SH, Earle JA, Stary JM, Lee S, Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuroreport 2001;12:3257-3262. (Pubitemid 33010654)
13. Honer WG, Falkai P, Bayer TA, Xie J, Hu L, Li HY, et al. Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex 2002; 12:349-356. (Pubitemid 34226059)
14. Pennington K, Dicker P, Dunn MJ, Cotter DR. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 2008;8:5097-5107.
15. Gibbons AS, Thomas EA, Dean B. Regional and duration of illness differences in the alteration of NCAM-180 mRNA expression within the cortex of subjects with schizophrenia. Schizophr Res 2009;112:65-71.
16. Barakauskas VE, Beasley CL, Barr AM, Ypsilanti AR, Li HY, Thornton AE, et al. A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. Neuropsychopharmacology 2010;35: 1226-1238.
17. Beasley CL, Honer WG, Bergmann K, Falkai P, Lütjohann D, Bayer TA. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord 2005;7:449-455. (Pubitemid 41419412)
18. Scarr E, Gray L, Keriakous D, Robinson PJ, Dean B. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord 2006;8:133-143. (Pubitemid 44026765)
19. Gray LJ, Dean B, Kronsbein HC, Robinson PJ, Scarr E. Region and diagnosis-specific changes in synaptic proteins in schizophrenia and bipolar I disorder. Psychiatry Res 2010;178:374-380.
20. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 2010;37:596- 603.
21. Dean B. Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia. Aust N Z J Psychiatry 2000;34:560-569. (Pubitemid 30496904)
22. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000;75:1729-1734.
23. Wang HD, Dunnavant FD, Jarman T, Deutch AY. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004;29:1230-1238. (Pubitemid 38780646)
24. Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004;56:570-550.
25. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord 2000;2:261-268.
26. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-69. (Pubitemid 34044408)
27. Citrome L, Jaffe A, Levine J, Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv 2002;53:1212.
28. Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol 2005;19:402-407. (Pubitemid 41003137)
29. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry 2000;5:142-149. (Pubitemid 30229428)
30. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003; 305:625-631. (Pubitemid 36459179)
31. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4354. (Pubitemid 9256559)
32. MacDonald ML, Eaton ME, Dudman JT, Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 2005;57:1041-1051. (Pubitemid 40603087)
33. Nakahara T, Nakamura K, Tsutsumi T, Hashimoto K, Hondo H, Hisatomi S, et al. Effect of chronic haloperidol treatment on synaptic protein mRNAs in the rat brain. Brain Res Mol Brain Res 1998;61:238-242. (Pubitemid 28511370)
34. Castillo MA, Ghose S, Tamminga CA, Ulery-Reynolds PG. Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biol Psychiatry 2010;67:208-216.
35. Cordeiro ML, Umbach JA, Gundersen CB. Lithium ions enhance cysteine string protein gene expression in vivo and in vitro. J Neurochem 2000;74:2365-2372. (Pubitemid 30314212)
36. Plenge P, Mellerup ET, Jørgensen OS. Lithium treatment regimens induce different changes in [3H]paroxetine binding protein and other rat brain proteins. Psychopharmacology (Berl) 1992;106:131-135.
37. Vawter MP, Thatcher L, Usen N, Hyde TM, Kleinman JE, Freed WJ. Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol Psychiatry 2002;7:571-578.
38. Zucker M, Weizman A, Harel D, Rehavi M. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs. Neuropsychobiology 2001;44:187-191. (Pubitemid 33036030)
39. Eastwood SL, Heffernan J, Harrison PJ. Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Mol Psychiatry 1997;2: 322-329. (Pubitemid 27450315)
40. Söllner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S, Tempst P, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature 1993;362:318- 324.
41. Edelmann L, Hanson PI, Chapman ER, Jahn R. Synapto-brevin binding to synaptophysin: a potential mechanism for controlling the exocytotic fusion machine. EMBO J 1995;14: 224-231.
42. Alder J, Kanki H, Valtorta F, Greengard P, Poo MM. Overexpression of synaptophysin enhances neurotransmitter secretion at Xenopus neuromuscular synapses. J Neurosci 1995;15:511-519.
43. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998;21:249-254. (Pubitemid 28239982)
44. Kaplan B, Ratner V, Haas E. Alpha-synuclein: its biological function and role in neurodegenerative diseases. J Mol Neurosci 2003;20:83-92. (Pubitemid 36693813)
45. Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A, et al. Alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J 2004;23: 4506-4516. (Pubitemid 39601975)
46. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010;329:1663-1667.
47. Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-252. (Pubitemid 30316525)
48. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 2002;22:8797-8807. (Pubitemid 35379049)
49. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000;20:3214- 3220.
50. Frasca A, Fumagalli F, Ter Horst J, Racagni G, Murphy KJ, Riva MA. Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex. Int J Neuropsychopharmacol 2008;11:591-595. (Pubitemid 351931828)
51. Büttner B, Reutter W, Horstkorte R. Cytoplasmic domain of NCAM 180 reduces NCAM-mediated neurite outgrowth. J Neurosci Res 2004;75:854-860. (Pubitemid 38296098)
52. Dityatev A, Dityateva G, Schachner M. Synaptic strength as a function of post- versus presynaptic expression of the neural cell adhesion molecule NCAM. Neuron 2000;26:207- 217.
53. Polo-Parada L, Bose CM, Plattner F, Landmesser LT. Distinct roles of different neural cell adhesion molecule (NCAM) isoforms in synaptic maturation revealed by analysis of NCAM 180 kDa isoform-deficient mice. J Neurosci 2004;24:1852-1864. (Pubitemid 38292796)
54. Doherty P, Fazeli MS, Walsh FS. The neural cell adhesion molecule and synaptic plasticity. J Neurobiol 1995;26:437- 446.
55. Jeannotte AM, Sidhu A. Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules. Eur J Neurosci 2007;26:1509-1520. (Pubitemid 47416513)
56. Jeannotte AM, McCarthy JG, Redei EE, Sidhu A. Desipramine modulation of alpha-, gamma-synuclein, and the norepinephrine transporter in an animal model of depression. Neuropsychopharmacology 2009;34:987-998.